NCT06560983 One Year Mortality and Morbidity With Hyperglycemia Among Acute Cerebrovascular Accident Patients in Emergency Department: A Cohort Study
| NCT ID | NCT06560983 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institute of medicine, Maharagjung medical campus |
| Condition | Cardiovascular Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 46 participants |
| Start Date | 2024-01-15 |
| Primary Completion | 2026-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 46 participants in total. It began in 2024-01-15 with a primary completion date of 2026-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The "One Year Mortality and Morbidity Outcome with Hyperglycemia among Acute Cerebrovascular Accident Patients in Emergency Department" is an extensive prospective cohort study designed to look into how hyperglycemia affects the short- and long-term outcomes of patients who present to the emergency room with acute cerebrovascular accidents (CVAs). Worldwide, cerebrovascular accidents are a major source of both death and morbidity. Research on the long-term consequences of hyperglycemia and its association with worse outcomes during the acute period of stroke is still underway. This study aims to close this information gap by investigating the relationship between the rates of immediate short- and one-year mortality rates and morbidity and hyperglycemia at the time of CVA presentation. The research design adopts a prospective cohort approach, aligning with established guidelines to ensure methodological rigor. Systematic random sampling will be employed, with a calculated sample size of 60. Patients with acute cerebrovascular accidents who are admitted to the emergency department will be a carefully chosen group for the research. The investigators will carefully gather important data, such as baseline clinical parameters, medical history, demographics, and blood glucose levels upon admission. Throughout a year, follow-up evaluations will be carried out regularly to monitor death rates and evaluate functional and neurological results in research participants using the modified Rankin score. The study will use a structured questionnaire for data collection, involving chart review and face-to-face interviews at specified intervals. Data analysis will include bivariate analysis, logistic regression, and Kaplan-Meier analysis to identify predictors of mortality and morbidity. The ultimate goal of this research is to improve patient care, prognosis, and long-term quality of life for those impacted by this critical medical condition by illuminating the prolonged effects of hyperglycemia in acute cerebrovascular accident patients and deepening our understanding of the intricate interactions between metabolic factors and stroke outcomes.
Eligibility Criteria
Inclusion Criteria: * Individuals exhibiting BEFAST-positive symptoms - meeting at least one of the criteria within 24 hours of symptom onset. * Confirmation of acute stroke through CT imaging. * Participants aged over 40 years. Exclusion Criteria: * Patients presenting with hypoglycemia * Transient Ischemic Attack (TIA). * Subdural hematoma cases. * Subarachnoid hemorrhage cases. * Diabetic Ketoacidosis. * Conditions mimicking stroke symptoms (e.g., sepsis, metabolic derangement, space-occupying lesions, hepatic encephalopathy). * History of bedridden patients. * Acute-on-chronic stroke cases. * Patients requiring assistance in daily activities. * History of trauma preceding the stroke.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06560983 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiovascular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06560983 currently recruiting?
Yes, NCT06560983 is actively recruiting participants. Contact the research team at bibekrajbhandarimg@gmail.com for enrollment information.
Where is the NCT06560983 trial being conducted?
This trial is being conducted at Kathmandu, Nepal, Kathmandu, Nepal.
Who is sponsoring the NCT06560983 clinical trial?
NCT06560983 is sponsored by Institute of medicine, Maharagjung medical campus. The trial plans to enroll 46 participants.